ENTX: Entera Bio Ltd. Stock

by  •  • Comments Off on ENTX: Entera Bio Ltd. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 79.94
Enterprise Value ($M) 71.28
Book Value ($M) 8.08
Book Value / Share 0.18
Price / Book 9.89
NCAV ($M) 7.66
NCAV / Share 0.17
Price / NCAV 10.43

Profitability (mra)
Return on Invested Capital (ROIC) -1.14
Return on Assets (ROA) -0.93
Return on Equity (ROE) -1.08

Liquidity (mrq)
Quick Ratio 7.63
Current Ratio 7.63

Balance Sheet (mrq) ($M)
Current Assets 8.97
Assets 9.39
Liabilities 1.31
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.18
Operating Income -9.59
Net Income -9.54
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -6.82
Cash from Investing -0.00
Cash from Financing 4.48

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-02 13G Opko Health, Inc. 8.10
01-06 13G Point72 Asset Management, L.P. 6.80
11-20 13G/A Knoll Capital Management, LLC 15.00 51.52
08-20 13G/A Centillion Fund Inc. 6.70 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-10 10-Q UNITED STATES

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 2,164 10,645 20.33
2025-04-16 3,658 17,411 21.01
2025-04-15 2,620 10,293 25.45

(click for more detail)

Similar Companies
ENLV – Enlivex Therapeutics Ltd. ENSC – Ensysce Biosciences, Inc.
ENTO – Entero Therapeutics, Inc. ENVB – Enveric Biosciences, Inc.
EPIX – ESSA Pharma Inc.


Financial data and stock pages provided by
Fintel.io